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Ziprasidone-induced skin reaction : A case 
report from Indian subcontinent. 
O.R JHIRWAL, AjlTAVASTHI 
ABSTRACT 
Ziprasidone, yet another atypical antipsychotic, has been associated, in this report, 
with development of photo-allergic skin reaction in therapeutic doses 
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Ziprasidone is a novel antipsychotic agent 
with a distinct pharmacological profile 
((•unasckara et al 2(X>2). It has antagonistic 
effects at 5HT% and D, receptors and is 
claimed to have no extrapyramidal, 
muscarinic, anti-a, or antihistaminic adverse 
effects and also a negligible effect on body 
weight (Zorn ct al 1999; Arnt ct al 1998). 
There is research evidence that Side effects 
of ziprasidone are minimal in contrast to 
other many anti psychotics. The overall 
incidence of treatment emergent adverse 
events in Ziprasidone treated patients did 
not exceed those in placebo-treated 
patients in two short term, double blind, 
randomized, multicentric studies. (Keck 
ct al 1998; Daniel et al 1999). Commonly 
reported adverse events with Ziprasidone 
include dyspepsia, nausea, dizziness, 
somnolence, abdominal pain and 
constipation. Skin reactions though 
reported, but rarely seen. 
The drug has been recently 
introduced in India. So far, no case of skin 
reaction with Ziprasidone has been reported. 
F.thnic issues are of importance in 
psychopharmacokigy and therefore, wc wish 
to place the following case on record. 
CASE 
Ms. S. a M> year old housewife presented to mir 
(Hit partem clinic with complaints of hearing voices. 
suspiciousness, fearful, abusive and aggressive 
towards neighbours for last l'/i years which began 
after land dispute with her aunt-in-law. 
History revealed that initially she perceived 
accusatory voices of relatives. Later, she started 
hearing commanding and commenting voices of 
her neighbours and parents due to which she 
remained fearful and suspicious. Occasionally, she 
became abusive and aggressive towards them. Since 
the onset of her illness, she had disturbed sleep, 
with declining performance and self-care. After 3 
months of illness, consultation was sought from a 
private psychiatrist but she discontinued treatment 
after 2 months. This was foDowed by consultation 
with faith - healers without any improvement. At 
last, they brought the patient to our Psychiatry out-
patient clinic. She had no past or family history of 
psychiatric illness. Mental status examination revealed 
persecutory delusions and auditory hallucinations. 
The latter were accusatory as well as commanding 
in nature and mainly persecutory in content. 
Routine laboratory investigations revealed no 
abnormality. A diagnosis of Schizophrenia-paranoid 
type (as per 1CD-10. WHO-IW2) was made and 
he was put on oral Ziprasidone -lOmg/day, titrated 
to 80 mg/day at the end of first week. Additionally, 
she was also prescribed oral Lorazcpam 2mg/day 
for her restlessness and sleep. 
Within the first week, she developed skin rashes 
over face which gradually extended to neck and 
back (Figure 1 and 2) region at the end of fortnight, 
by which time her psychotic symptoms had started 
improving remarkably. Patient's husband became 
concerned of this skin reaction and brought her 
back to the outpatient clink. Skin specialist diagnosed 
this reaction to be polymorphonuclear light eruptions 
(PMI.II) probably due to some drug. The patient 
was advised to refrain from that drug and prescribed 
topical steroids and oral antihistaminic and antibiotics. 
PMLE due to Ziprasidone at Neck region 
PMLE due to Ziprasidone at Back 
After stopping oral Ziprasidone, skin rashes gradually 
subsided within a week. During this period, oral _, 
Lorazcpam was continued. A repeat deramatologic 
consultation was taken and the dermatologist opined 
that the skin lesions had subsided, however, there 
were post inflammatory scars. Oral Risperidone 
6mg/day along with oral Lorazcpam 2mg/day were 
started at this point. Mr. S maintained her 
improvement with this treatment and no fresh skin 
lesions have appeared. 
DISCUSSION 
The appearance and disappearance of 
skin reaction in association with the 
introduction and withdrawal of Ziprasidone, 
indicate that the symptoms were likely to 
have been drug induced. 
Photosensitive reactions are produced by 
interactions of a drug with light energy that, 
depending on the particular interaction, can 
range from the ultraviolet spectrum to the 
visible light spectrum. The drug eruption is 
thus limited to body areas exposed to light 
such as face, neck, arms, back of the hands, 
the V area of the chest and the anterior 
and the inferior aspect of the legs. (Deswartc 
(64) ZIPRASIDONE-INDUCED SKIN REACTION 
1972). 
Drug induced photosensitivity can be 
cither phototoxic (direct thermal injury) or 
photoallcrgic. In photoallcrgic reactions, the 
solar radiation alters the drug or its 
metabolites in vivo forming a reactive 
compound or complete hapten that elicits 
an immune response in form of skin 
lesions. (Kaplan 1984). 
In premarketing trials with Ziprasidone, 
about 5% of patients developed rash and/ 
or urticaria which led to discontinuation of 
treatment in about one-sixth of these cases. 
Most patients improved promptly with 
adjunctive treatment with antihistamines or 
steroids and/or upon discontinuation of 
Ziprasidone, and all patients experiencing 
these events were reported to recover 
completely (data on file; Pfizer, 2002). 
Ziprasidone should be discontinued in 
patients who develop a rash for which an 
alternative aetiology can not be found 
(Gunasckara et al 2002). 
Re-challenge with the drug was not tried 
in this case as the patient maintained 
improvement with Risperidone. Pooling 
similar reports may be more rewarding. 
To conclude, although Ziprasidone is 
a promising new antipsychotic that has 
shown significant efficacy in the oral 
treatment of patients with schizophrenia 
and schizo-affcctivc disorder, but its safety 
profile should be explored in detail in 
Indian subcontinent. The present work 
is a single case report, hence more 
reporting is essential to confirm our 
views. 
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